.png)
.png)
Latest news from BIA
BIA welcomes new NIHR framework for restarting research activities in the UK
Commenting on the NIHR 'Framework for restart' released today, Steve Bates OBE, Chief Executive of the BIA said:
BIA responds to government approach to Northern Ireland Protocol
Commenting on the Government’s approach to the Northern Ireland Protocol released yesterday, Steve Bates OBE, Chief Executive of the BioIndustry Association said:
BIA welcomes financial support for biotechs during COVID-19 disruption
A new support fund for innovative firms struggling to access equity finance during the COVID-19 disruption has opened for applications today (20 May). The Future Fund, run by the British Business Bank, will provide convertible loans of between £125,000 and £5m to businesses if they can also secure matched funding from third-party investors.
BIA responds to publication of draft UK-EU free trade agreement
Commenting on the publication of draft UK-EU free trade agreement text released today Steve Bates OBE, Chief Executive of the BIA said:
Biosphere businesses receive funding boost to support the global fight against COVID-19
TWO businesses based in The Biosphere on Newcastle Helix have been awarded funding to accelerate their innovations to support the global fight against the COVID-19. Innovate UK, the UK’s innovation agency has awarded ExplantLab and Atelerix almost £50,000 each to fast track their ideas and research.
Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit. This kit is for research use only and launched under the T-SPOT Discovery brand. This research kit could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic, which in turn could help to bring nations out of their current lockdowns in a faster, safer and more controlled manner.
Locate Bio announces the appointment of John von Benecke as CEO
Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, announced that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline.
Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins
CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield
CEO Update|Monday 01 June
The NHS Test and Trace Programme is launched, Gilead’s remdesivir becomes available under the Early Access to Medicines Scheme and BIA members continue to ramp up UK vaccine manufacturing capacity. Plus, the BIA innovates this week with the popular Women in Biotech series moving to a virtual setting!
Guest Blog|Reducing the use of animals in drug development whilst ensuring human safety
The use of animals in research continues to rank highly in the public consciousness, with a 2018 Ipsos MORI poll showing that three-fifths of people are interested in the methods used by scientists to replace, reduce and refine the use of animals in research (the 3Rs). The UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research (the NC3Rs) is committed to furthering this goal. Its programme includes a long-standing collaboration with the pharmaceutical industry that has led to changes in company practice and regulatory guidelines.
CEO Update|Tuesday 26 May
AstraZeneca receives $1.2bn to scale-up and deliver Oxford’s COVID-19 vaccine, antibody testing gains momentum as a deal is struck between Roche and the NHS and details start to emerge on the future of the UK’s relationship with the EU.
Guest Blog|A reflection on the Lighthouse Lab journey so far
Last month, UK government approached Medicines Discovery Catapult, based at Alderley Park, to coordinate the establishment of the national megalabs for the testing of COVID-19.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector | BIA update: October 2019 - January 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.
Global and growing - UK biotech financing in 2019
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.
UK life sciences: Catalysing investment and growth
This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
BIA biotech manifesto 2019
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
